Combination therapy for reducing the risks associated with cardiovascular disease
US6403571B2 · kind B2 · utility
3Cited by
4References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 18, 2001 |
| Grant date | Jun 11, 2002 |
| Priority date | — |
| Expiry date | Jan 18, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K45/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The instant invention involves a combination therapy and pharmaceutical compositions comprised of a therapeutically effective amount of a cholesterol reducing agent such as an HMG-CoA reductase inhibitor in combination with a platelet aggregation inhibitor which is useful for inhibiting platelet aggregation, for inhibiting the formation of thrombotic occlusions, and for treating, preventing and reducing the risk of occurrence of cardiovascular and cerebrovascular events and related vaso-occlusive disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.